TARS — Tarsus Pharmaceuticals Share News
0.000.00%
Last trade - 00:00- $3.47bn
- $3.09bn
- $451.36m
Tarsus Pharmaceuticals Inc expected to post a loss of 92 cents a share - Earnings Preview
Brief: Tarsus Pharmaceuticals Q1 Operating Expenses USD 65.298 Million
Tarsus Pharmaceuticals Inc expected to post a loss of $1.20 a share - Earnings Preview
Brief: Tarsus Strengthens Financial Position And Refinances Existing Debt With $200 Million Non-Dilutive Financing Commitment From Pharmakon
U.S. RESEARCH ROUNDUP-Highpeak Energy, Nordstrom, Victoria'S Secret & Co
U.S. STOCKS ON THE MOVE-Old Republic, TDCX, Repay Holdings
Tarsus Pharma slides on $100 mln stock offering
Brief: Tarsus Announces Pricing Of $100 Mln Public Offering
Brief: Tarsus Pharmaceuticals Inc Files For Mixed Shelf Size Not Disclosed - SEC Filing
Brief: Tarsus Pharmaceuticals Announces Proposed $100 Million Public Offering
Tarsus Pharmaceuticals Inc reports results for the quarter ended in December - Earnings Summary
Brief: Tarsus Pharmaceuticals Q4 Basic EPS USD -1.31
Tarsus Pharmaceuticals Inc expected to post a loss of $1.36 a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Wayfair Inc, Remitly Global, Monopar Therapeutics
Tarsus Pharma up on positive trial data for Lyme disease prevention drug
Brief: Tarsus Announces Topline Results From Phase 2a Trial Evaluating TP-05 (lotilaner) for Prevention of Lyme Disease
U.S. STOCKS ON THE MOVE-Coty, Planet Fitness, Quanta Services
Tarsus Pharma up on positive trial data for Lyme disease prevention drug
Brief: Tarsus Pharmaceuticals Inc Says FDA Discussion Planned For 2024 For TP-03